Mark your calendars for the 21st International Conference on Alzheimer’s Drug Discovery!
October 5-6, 2020
UPDATE CONCERNING COVID-19 (NOVEL CORONAVIRUS)
We wish to inform you that our conference preparations continue as planned while the actual event is set to take place October 5-6, 2020 in Jersey City, NJ.
We are closely monitoring the COVID-19 situation, and will continue to monitor the CDC recommendation and information for travel. The organizers are fully committed to taking the appropriate precautions to provide a healthy environment for attendees, presenters and exhibitors.
With the conference scheduled for October, we hope things will have returned to normal. However, we are making contingency plans and should there be any changes in this evolving situation, updates will be provided on the website and via email.
Until then, we thank you for your engagement and look forward to welcoming you to the conference in October!
This annual conference will showcase the innovative approaches of ADDF funded scientists and their newest results. Attendees will have the opportunity for networking and partnering discussions.
The conference offers a wide range of registration options (including early-bird rates) for researchers from the nonprofit, academic, biotech, and pharma sectors.
- Highlight scientific progress on drug development programs aimed at treating Alzheimer’s disease and related dementias.
- Increase networking opportunities for scientists to share information and resources.
- Foster interdisciplinary and public-private partnerships and alliances.
The purpose for this annual Alzheimer’s Drug Discovery Foundation conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging.
Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.
The 2019 edition of this conference attracted close to 130 attendees from around the world. Attendees included:
- Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases and CNS
- Business development and licensing professionals
- Alliance management professionals
- Venture capitalists and other investors
- Graduate students, PhD candidates and post-doctoral fellows.